SYNERGY: Tofisopam has obtained the drug registration certificate in South Korea

According to the Zhitong Finance APP, SYNERGY announced that the company recently received the drug registration certificate for tolvaptan from the Ministry of Food and Drug Safety (MFDS) of South Korea. Tolvaptan is an oral anticoagulant primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism

According to the Zhitong Finance APP, SYNERGY (300636.SZ) announced that the company recently received the drug registration certificate for tolvaptan from the Ministry of Food and Drug Safety (MFDS) of South Korea. Tolvaptan is an oral anticoagulant primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism